One of the main hemophilia symptoms is excessive bleeding, which can occur into the joints. This type of bleeding can lead to joint damage, or joint arthropathy. Joint damage can limit movement and the ability to exercise for people living with this bleeding disorder.
Hemophilia News Today brought you coverage of the latest developments in research and advances in treatments for hemophilia in 2023. Here we’ve compiled a list of the top 10 most-read articles published on our site last year. We hope to continue being a resource for the hemophilia community…
Embracing the start of 2024, I reflect on the friendships I’ve made within the hemophilia community over the past year. As a woman navigating the complexities of hemophilia B and von Willebrand disease, these connections have become a source of strength and solidarity for me. Each person…
Scientists in Taiwan have created a new point-of-care device to diagnose hemophilia type A and determine a person’s blood type using just a small sample of blood. The device “is especially suitable for usage in emergency or natural disasters to provide quantitative testing in rescue and relief operations,” the…
Hemophilia joint health care involves treatments, physiotherapy, and lifestyle adjustments such as doing low-impact exercises, following a well-balanced nutrition plan, and maintaining good mental health.
The once-weekly injection therapy marstacimab is being considered for approval in both the U.S. and Europe for people with hemophilia A and hemophilia B who don’t have inhibitors. The U.S. Food and Drug Administration (FDA) is expected to decide on it in late 2024, while a decision from the European…
Hemophilia, with its potential for spontaneous bleeding episodes and the need for regular medical interventions, can have a significant effect on the mental well-being of people living with this bleeding disorder.
NovoSeven (eptacog alfa [activated]) is a bypassing agent that’s approved to treat bleeding episodes, including those occurring during surgery, in adults and children with hemophilia A or B who have developed inhibitors — neutralizing antibodies against certain clotting factors.
Xyntha (moroctocog alfa) is a recombinant, or man-made, clotting factor replacement therapy approved to prevent and treat bleeds, including those occurring during surgery, in people with hemophilia A.
Sevenfact (eptacog beta) is a bypassing agent that’s approved to treat bleeding episodes in people with hemophilia A or hemophilia B who developed inhibitors, or neutralizing antibodies, against clotting factor VIII (FVIII) or factor IX (FIX).
Get regular updates to your inbox.
